FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapiesCombination therapies involving Roche and AbbVie’s cancer drug Venclexta have been formally approved by the FDA in acute Share XFDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapieshttps://pharmaphorum.com/news/fda-grants-full-approval-for-roche-abbvies-venclexta-in-aml-combination-therapies/
NICE backs NHS use for Astellas’ Xospata after rethinkNICE has recommended regular NHS funding for Astellas’ Xospata (gilteritinib) monotherapy for certain adult patients with acute myeloid leukaemia. In final draft guidance Share XNICE backs NHS use for Astellas’ Xospata after rethinkhttps://pharmaphorum.com/news/nice-backs-nhs-use-for-astellas-xospata-after-rethink/
Gilead trumpets data with newly-bought magrolimab in blood cancersJust three months after acquiring Forty Seven for $4.9 billion, Gilead has reported positive data on magrolimab, the Share XGilead trumpets data with newly-bought magrolimab in blood cancershttps://pharmaphorum.com/news/gilead-magrolimab-blood-cancer-asco/
New combination trial firms up Venclexta’s prospects in AMLAbbVie and Roche have been thrown a lifeline for their Venclexta drug in acute myeloid leukaemia (AML), just Share XNew combination trial firms up Venclexta’s prospects in AMLhttps://pharmaphorum.com/news/new-combination-trial-firms-up-venclextas-prospects-in-aml/
AbbVie/Roche’s Venclexta fails in confirmatory AML trialAbbVie and Roche’s Venclexta has failed to significantly improve overall survival in an acute myeloid leukaemia (AML) trial Share XAbbVie/Roche’s Venclexta fails in confirmatory AML trialhttps://pharmaphorum.com/news/abbvie-roches-venclexta-fails-in-confirmatory-aml-trial/
BMS preps filings for leukaemia maintenance therapy CC-486Celgene’s pipeline has delivered another new drug filing for Bristol-Myers Squibb, thanks to positive results for oral azacitidine Share XBMS preps filings for leukaemia maintenance therapy CC-486https://pharmaphorum.com/news/bms-preps-filings-for-leukaemia-maintenance-therapy-cc-486/
Astellas gets EU approval for AML drug XospataThe European Commission has approved Astellas’ Xospata (gilteritinib) for patients with relapsed or refractory FLT3-positive acute myeloid leukemia Share XAstellas gets EU approval for AML drug Xospatahttps://pharmaphorum.com/news/astellas-gets-eu-approval-for-aml-drug-xospata/
Astellas maintains lead over Daiichi Sankyo with CHMP okay for XospataAstellas’ FLT3 inhibitor for acute myeloid leukaemia (AML) – Xospata – has been recommended for approval in Europe, Share XAstellas maintains lead over Daiichi Sankyo with CHMP okay for Xospatahttps://pharmaphorum.com/news/astellas-maintains-lead-over-daiichi-sankyo-with-aml-drug-xospata/
Oncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and moreAZ and Daiichi Sankyo announced positive top-line results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan, Share XOncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and morehttps://pharmaphorum.com/views-and-analysis/oncology-round-up-az-and-daiichi-score-key-trial-win-with-breast-cancer-antibody-and-more/
